Results 1 to 10 of about 2,253,886 (314)

Technical report: liquid overlay technique allows the generation of homogeneous osteosarcoma, glioblastoma, lung and prostate adenocarcinoma spheroids that can be used for drug cytotoxicity measurements

open access: yesFrontiers in Bioengineering and Biotechnology, 2023
Introduction: The mechanisms involved in cancer initiation, progression, drug resistance, and disease recurrence are traditionally investigated through in vitro adherent monolayer (2D) cell models.
Camille Jubelin   +15 more
doaj   +1 more source

ProNGF promotes brain metastasis through TrkA/EphA2 induced Src activation in triple negative breast cancer cells

open access: yesExperimental Hematology & Oncology, 2023
Background Triple-Negative Breast Cancer is particularly aggressive, and its metastasis to the brain has a significant psychological impact on patients' quality of life, in addition to reducing survival.
Julien Cicero   +27 more
doaj   +1 more source

O-GlcNAcylation inhibition redirects the response of colon cancer cells to chemotherapy from senescence to apoptosis

open access: yesCell Death and Disease
The potential use of pro-senescence therapies, known as TIS (Therapy-Induced Senescence), for the treatment of colorectal cancer (CRC) generated significant interest since they require lower doses compared to those required for inducing apoptosis ...
Ingrid Loison   +7 more
doaj   +1 more source

Lipid Metabolism and Resistance to Anticancer Treatment

open access: yesBiology, 2020
Metabolic reprogramming is crucial to respond to cancer cell requirements during tumor development. In the last decade, metabolic alterations have been shown to modulate cancer cells’ sensitivity to chemotherapeutic agents including conventional and ...
Nicolas Germain   +5 more
doaj   +1 more source

MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)‐dependent oncogenic driver in vitro and in humanised HGF knock‐in mice

open access: yesMolecular Oncology, 2023
Exon skipping mutations of the MET receptor tyrosine kinase (METex14), increasingly reported in cancers, occur in 3–4% of non–small‐cell lung cancer (NSCLC). Only 50% of patients have a beneficial response to treatment with MET‐tyrosine kinase inhibitors
Marie Fernandes   +24 more
doaj   +1 more source

Macrophage Subsets in Obesity, Aligning the Liver and Adipose Tissue

open access: yesFrontiers in Endocrinology, 2020
The increasing prevalence of obesity is accompanied by a rising incidence in metabolic syndrome and related pathologies such as non-alcoholic fatty liver disease. Macrophages are hypothesized to play central roles in these diseases, through their role as
Anneleen Remmerie   +6 more
doaj   +1 more source

Emerging roles of MITF as a crucial regulator of immunity

open access: yesExperimental and Molecular Medicine
Microphthalmia-associated transcription factor (MITF), a basic helix-loop-helix leucine zipper transcription factor (bHLH-Zip), has been identified as a melanocyte-specific transcription factor and plays a critical role in melanocyte survival ...
Aram Lee, Jihyun Lim, Jong-Seok Lim
doaj   +1 more source

Long non-coding RNA UCA1 modulates SMARCA2-containing SWI/SNF chromatin remodeling complexes in human colorectal cancer

open access: yesiScience
Summary: Differential long non-coding RNA (lncRNA) expression has been correlated to clinical characteristics of colorectal cancers (CRCs), which are the second leading cause of cancer-related deaths.
Bernadette Neve   +26 more
doaj   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

open access: yesMolecular Oncology
According to the seed and soil hypothesis, the organ specificity of metastasis is not a random process and depends on multiple tumor‐intrinsic and microenvironmental factors.
Eduardo Candeal   +4 more
doaj   +1 more source

Induction of AML cell differentiation using HOXA9/DNA binding inhibitors as a potential therapeutic option for HOXA9‐dependent AML

open access: yesHemaSphere
The mainstay of acute myeloid leukemia (AML) treatment still relies on traditional chemotherapy, with a survival rate of approximately 30% for patients under 65 years of age and as low as 5% for those beyond.
Mélanie Lambert   +11 more
doaj   +1 more source

Home - About - Disclaimer - Privacy